• DNDi-20_Logo_No-Tagline_EN_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia/India
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi-20_Logo_No-Tagline_EN_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia/India
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Events > Lives in the Balance – NY > Page 2

Lives in the Balance – NY

13-14 December 2012

New York City

Share on twitter
Share on facebook
Share on linkedin
Share on email
Share on print
  • Agenda
    • Overview
    • Agenda
    • Videos

Agenda

Thursday, December 13, 2012

Progress and Shortcomings of the Past Decade for R&D for Neglected Patients

8:00-9:00 amBREAKFAST
9:00-9:15 amWELCOMING REMARKS

– Philip Landrigan, MD, Dean of the Global Health Program at Mount Sinai School of Medicine
– Deane Marchbein, MD, President of MSF-USA
– Rachel Cohen, Regional Executive Director DNDi North America
9:15-9:45 amKEYNOTE ADDRESS

Anthony S. Fauci, MD, Director, National Institute of Allergy and Infectious Diseases, US National Institutes of Health
9:45-11:15 amPANEL 1.1: Global Progress and Shortcomings of the Past Decade

Panel Chair: Dyann Wirth, PhD, Richard Pearson Strong Professor of Infectious Diseases, Harvard School of Public Health

Presenters:
– Manica Balasegaram, MD, Executive Director, MSF Access Campaign – The urgent need for new tools for DR-TB
– Julio A. Urbina, PhD, Venezuelan Institute for Scientific Research – Reaching neglected patients with Chagas treatment
– F. Marc LaForce, MD, Director, Technical Services, Serum Institute of India, Ltd – Overview of vaccine initiatives of the past decade

Discussants:
– Atadjan Karimovich Khamraev, MD, Vice-Chairman of the Supreme Assembly of the Autonomous Republic of Karakalpakstan
– Peter J. Hotez, MD, PhD, Dean, National School of Tropical Medicine, Baylor College of Medicine
– H.E. Dr. Josephine Ojiambo, MB ChB, MPH, Ambassador, Deputy Permanent Representative of the Republic of Kenya to the United Nations
11:15-11:30 am BREAK
11:30-1:00 pmPANEL 1.2: New Tools and the R&D Landscape

Panel Chair: Els Torreele, PhD, Director, Open Society Public Health Program’s Access to Essential Medicines Initiative

Presenters:
– Carlos Morel, MD DSc, Scientific Coordinator, Center for Technological Development in Health (CDTS) at the Oswaldo Cruz Foundation (Fiocruz) – What steps have been taken to address gaps in R&D for neglected patients over the last twenty years: A View from the South
– Jean-Herve Bradol, MD, Research Director, MSF’s Centre de réflexion sur l’action et les savoirs humanitaires (CRASH) – Fatal Imbalance: Update and expanded review of new treatments and current pipeline of clinical trials for neglected diseases, 2000-2011
– John-Arne Røttingen, MD, PhD, Chair, Consultative expert working group on research and development (CEWG) – A possible framework for stimulating medical innovations for neglected patients

Discussants:
– Lucy Chesire, Director, TB ACTION Group, Kenya
– James Love, Director, Knowledge Ecology International
– Christian Loucq, MD, Director General International Vaccine Institute (IVI)
1:00-2:00 pmLUNCH

HIGH LEVEL ROUNDTABLE DISCUSSIONS

2:00-3:30 pmOpening Talk: Jim Y. Kim, MD, President, World Bank Group (Video Address)

Roundtable 1.3: Setting Priorities for Global Health to Ensure Innovation and Access

Moderator: Gavin Yamey, MD, MA, MRCP, Lead of E2Pi, the Evidence-to-Policy Initiative at the UCSF Global Health Group

Panelists:
– Carlos Gadelha, PhD, Secretary of Science, Technology and Strategic Products (SCTIE), Ministry of Health, Brazil
– Marie-Paule Kieny, PhD, Assistant Director-General – Innovation, Information, Evidence and Research, World Health Organization
– Dan Hartman, MD, Director, Integrated Development, Global Health Program, Bill & Melinda Gates Foundation
– ‘Rolake Odetoyinbo, Director, Positive Action for Treatment Access (PATA), Nigeria
Unni Karunakara, MD, International President of MSF
3:30-3:45 pmBREAK
3:45-5:15 pmRoundtable 1.4: Mechanisms for Facilitating Financing and Norm Setting

Moderator: Ellen ‘t Hoen, LL.M., Research Fellow at the University of Amsterdam and Senior Advisor of the Medicines Patent Pool

Panelists:
– Roger I. Glass, MD, PhD, Director of the Fogarty International Center and Associate Director for International Research by NIH, US National Institutes of Health
– Christopher A. Viehbacher, Chief Executive Officer, Sanofi
– Gichinga Ndirangu, Africa Coordinator, Health Action International (HAI)
– Samir K. Brahmachari, PhD, Director General, Council of Scientific and Industrial Research, India
– Bernard Pecoul, MD, Executive Director of Drugs for Neglected Diseases initiative (DNDi)
5:15-5:30 pmClosing Remarks

Marie-Pierre Allie, MD, President of MSF in France
The need to accelerate the delivery of medical innovations to neglected patients

Friday, December 14, 2012

How to Accelerate the Benefits from New Tools for DR-TB, Chagas disease, and Vaccines

8:00-8:55 amBREAKFAST
8:55-9:00 amWELCOMING REMARKS

Bennett Shapiro, PureTech Ventures and DNDi Board Member

TECHNICAL SESSIONS

9:00-10:15 am2.1 DR TB

Moderator: Arjan Hehenkamp, General Director, MSF Operational Center Amsterdam

Short Presentations to set the stage:
– Francis Varaine, MD, Head of MSF’s TB Working Group – Outcomes with current DR-TB treatment and urgent need for change
– Mel Spigelman, MD, President and CEO, TB Alliance – The current pipeline and scheduled plans for when molecules will be available
– Dalene von Delft, MD– A patient’s perspective of current DR-TB treatment
Panel Discussion:
– Atadjan Karimovich Khamraev, Vice-Chairman of the Supreme Assembly of the Autonomous Republic of Karakalpakstan
– Carole Mitnick, ScD, Assistant Professor of Global Health and Social Medicine, Harvard Medical School
– Mark Harrington, Executive Director, Treatment Action Group (TAG)Wim Parys, MD, Global Head, Infectious Diseases, Janssen Infectious Diseases BVBA
10:15-10:30 amBREAK
10:30-11:45 am2.2. Chagas disease

Moderator: Isabela Ribeiro, MD, Head of Chagas Clinical Program, DNDi

Short Presentations Setting the Stage:
– Jose Rivero, International Federation of People Suffering from Chagas Disease, Spain – A patient’s perspective of Chagas disease treatment
– Carolina Batista, MSF Brazil and Henry Rodriguez, MD, MSF Head of Mission in Bolivia and Paraguay– Obstacles and challenges of treating Chagas disease
– Faustino Torrico, M.D., Ph.D., Professor, Faculty of Medicine, Universidad Mayor de San Simon, Cochabamba, Bolivia – The current pipeline for Chagas disease

Panel Discussion:
– Jaime Lazovski, Secretary of Health Relations and Research, Ministry of Health, Argentina
– Sheba Meymandi, MD, Director, Centre of Excellence for Chagas Disease, Olive View/UCLA Medical Center
– Sonia Tarragona, General Director, Foundation Mundo Sano, Argentina
– Pedro Alonso, MD, Director, Barcelona Center for International Health Research (CRESIB), University of Barcelona
11:45-1:00 pm2.3. Vaccines

Moderator: Robert Steinglass, Immunization Senior Advisor, John Snow, Inc. (JSI) and Immunization Team Leader, MCHIP

Short Presentations Setting the Stage:
– Samba Ousmane Sow, MD, Center for Vaccine Development-Mali (CVD-Mali) – A case study on using TT-Uniject in Mali
– Rebecca Grais, PhD , Epicentre – Optimizing vaccinations in emergencies – what products are needed

Panel Discussion:
Fred Were, MD, Chairman of the Kenya Pediatric Association
– F. Marc La Force, MD, Serum Institute of India
– Nina Schwalbe, Managing Director, Policy & Performance, GAVI Alliance
– Paul Herrling, PhD, Professor, Chair Novartis Institute for Tropical Diseases, Novartis Pharma AG
1:00-1:10 pmCLOSING REMARKS / CONFERENCE WRAP UP

Marcel Tanner, PhD, Director of the Swiss Tropical and Public Health Institute and Chair of the Board of Directors, DNDi
1:10 pmLUNCH
Pages: Page 1, Page 2, Page 3

Other events

Loading...
13-14 March 2023

Putrajaya, Malaysia

Tropical Infectious Diseases Conference 2023

6 February 2023, 5 PM Madrid

Madrid, Spain and online

La Salud Global y las Enfermedades Tropicales Desatendidas en su día mundial

30 January 2023, 5-8 PM Hamburg

Hamburg, Germany

World NTD Day 2023: Snack & Talk about NTDs

29 January 2023

Referral Hospital, Baniapur, Saran, Bihar

Honouring frontline heroes of NTDs

See all

Stay connected

Get our latest news, personal stories, research articles, and job opportunities. 

Facebook-f
Twitter
Instagram
Linkedin-in
Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License   
We use cookies to track our audience and improve our content. By clicking 'Accept All', you are agreeing to our use of cookies. Click on 'Customize' to accept only some cookies.
Customize
ACCEPT ALL
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-advertisement1 yearSet by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
CookieLawInfoConsent1 yearRecords the default button state of the corresponding category & the status of CCPA. It works only in coordination with the primary cookie.
PHPSESSIDsessionThis cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
CookieDurationDescription
elementorneverThis cookie is used by the website's WordPress theme. It allows the website owner to implement or change the website's content in real-time.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
CookieDurationDescription
_ga2 yearsThe _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
_ga_16Q5RH3XRG2 yearsThis cookie is installed by Google Analytics.
_gat_UA-10302561-11 minuteA variation of the _gat cookie set by Google Analytics and Google Tag Manager to allow website owners to track visitor behaviour and measure site performance. The pattern element in the name contains the unique identity number of the account or website it relates to.
_gid1 dayInstalled by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.
_hjAbsoluteSessionInProgress30 minutesHotjar sets this cookie to detect the first pageview session of a user. This is a True/False flag set by the cookie.
_hjFirstSeen30 minutesHotjar sets this cookie to identify a new user’s first session. It stores a true/false value, indicating whether it was the first time Hotjar saw this user.
_hjIncludedInPageviewSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's pageview limit.
_hjIncludedInSessionSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's daily session limit.
_hjSession_112884430 minutesHotjar sets this cookie.
_hjSessionUser_11288441 yearHotjar sets this cookie.
CONSENT2 yearsYouTube sets this cookie via embedded youtube-videos and registers anonymous statistical data.
Targeting
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
SAVE & ACCEPT
Powered by CookieYes Logo